Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Salivary Glands Tumors × Abiraterone Acetate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 153 Neoplasm Metastasis 12 Prostatic Neoplasms, Castration-Resistant 11 Neoplasms 6 Metastatic Castration-resistant Prostate Cancer 5 Metastatic Castration Resistant Prostate Cancer 5 Breast Neoplasms 5 Prostate Cancer Metastatic 4 Urogenital Neoplasms 3 Metastatic Castration-Resistant Prostate Cancer 3 Genital Neoplasms, Male 3 Prostatic Diseases 2 Neoplasms by Site 2 Genital Diseases, Male 2 Adenocarcinoma 2 Urinary Bladder Neoplasms 1 Stage II Prostate Adenocarcinoma 1 Sleep Initiation and Maintenance Disorders 1 Salivary Glands Tumors 1 Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone 1 Prostate Adenocarcinoma 1 Pharmacogenetic Study 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Neoplasms 1 Oligometastatic Prostate Carcinoma 1 Newly Diagnosed Oligometastatic Prostate Cancer 1 NSCLC Harboring NRG1 Fusion 1 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1 Metastatic Hormone Refractory Prostate Cancer 1 Metastatic Castration-sensitive Prostate Cancer 1

Interventions

Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02867852 2021-03-03

SG-ABI14

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Salivary Glands Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡